Glucagon-like Peptide 1 Receptor (GLP-1R) Signaling Inhibits Aeroallergen-Induced IL-33 Release and Reduces Group 2 Innate Lymphoid Cell (ILC2) Activation In Vivo

Toki, Shinji; Goleniewska, Kasia; Reiss, Sara; Zhang, Jian; Bloodworth, Melissa H.; Stier, Matt T.; Zhou, Weisong; Newcomb, Dawn C.; Boyd, Kelli L.; Niswender, Kevin D.; Peebles, Stokes

doi:10.1016/j.jaci.2016.12.217

Search citation statements

Order By: Relevance

Paper Sections

Select...

Therapeutic Benefits Of Glp-1 In Asthma1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most recently, it has been demonstrated that GLP-1 may inhibit aeroallergen-induced IL-33 release and further reduce group 2 innate lymphoid cell activation (Toki et al, 2017). In another murine study, GLP-1R agonists, liraglutide and exenatide, improved survival and pulmonary function (Viby et al, 2013).…”

Section: Therapeutic Benefits Of Glp-1 In Asthmamentioning

confidence: 99%

Glucagon-like peptide 1: A potential anti-inflammatory pathway in obesity-related asthma

Nguyen

Linderholm

Haczku

et al. 2017

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Alterations in arginine metabolism and accelerated formation of advanced glycation end-products (AGEs), crucial mechanisms in obesity-related asthma, can be modulated by glucagon-like peptide 1 (GLP-1). L-arginine dysregulation in obesity promotes inflammation and bronchoconstriction. Prolonged hyperglycemia, dyslipidemia, and oxidative stress leads to production of AGEs, that bind to their receptor (RAGE) further potentiating inflammation. By binding to its widely distributed receptor, GLP-1 blunts the effects of RAGE activation and arginine dysregulation. The GLP-1 pathway, while comprehensively studied in the endocrine and cardiovascular literature, is under-recognized in pulmonary research. Insights into GLP-1 and the lung may lead to novel treatments for obesity-related asthma.

show abstract

Section: Therapeutic Benefits Of Glp-1 In Asthmamentioning

confidence: 99%